Jail-to-Freedom: which shot keeps opioid addiction in check?

NCT ID NCT04408313

Ongoing Disease control Sponsor: Friends Research Institute, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two long-acting injectable medications—extended-release naltrexone and extended-release buprenorphine—for people with opioid use disorder who are leaving jail. 240 participants from Maryland jails will receive monthly shots for six months after release. The goal is to see which medication helps them stay in treatment and avoid opioid use or overdose.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: extended-release naltrexone and extended-release buprenorphine
What this could lead to: If this trial succeeds, it could show which long-acting medication works better to help people leaving jail stay in treatment and avoid relapse or overdose.
What could go wrong: This is a mid-stage trial with 240 participants, so results may not apply to everyone. Both medications have side effects and may not work for all individuals.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OPIOID-USE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

opiate dependence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OPIOID-USE DISORDER

Contacts and locations

Locations

Friends Research Institute

Baltimore, Maryland, 21201, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.